Business
InspireMD Reports First Quarter 2025 Financial Results
Management to host investor conference call today, May 9th, at 8:30am ETMIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the
About this update from Inspiremd Inc.
[{"type":"image","alt":"InspireMD Inc.","displaySize":"","headline":null,"caption":"InspireMD Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":206,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/de2f14a2bd34f4c4ce9ff024cee316df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_AZpeZW_vtC.eOzsQRByqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/de2f14a2bd34f4c4ce9ff024cee316df","width":206,"height":42}},"lazy":false},{"type":"text","content":"Management to host investor conference call today, May 9th, at 8:30am ET","length":72,"tagName":"p"},{"type":"text","content":"MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025.","length":285,"tagName":"p"},{"type":"text","content":"Business Highlights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025","length":235,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launch","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued enrollment with excellent pace in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":475,"olType":false},{"type":"text","content":"Marvin Slosman, CEO of InspireMD, commented: “In the first quarter we continued to drive commercial adoption of our technology in our served markets, while laying a strong operational and strategic foundation for upcoming transformational milestones. With a clear roadmap for commercial expansion and a disciplined focus on execution, we’ve built and trained a world-class commercial team—ready to execute at scale upon potential FDA PMA approval. We’re energized by the momentum and confident in the opportunities on the horizon.”","length":531,"t...